Adriamycin-resistant U87 cell model and application thereof

A cell model and doxorubicin-resistant technology, applied in animal cells, tumor/cancer cells, vertebrate cells, etc., can solve the problems of poor effect and easy drug resistance, and achieve good drug resistance stability

Inactive Publication Date: 2015-09-30
JINSHAN HOSPITAL FUDAN UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The chemotherapeutic drug doxorubicin (DOX) promotes tumor cell apoptosis through the intracellular pathway. It is often used in the treatment of glioma, but it is prone to drug resistance, and the effect of chemotherapy after drug resistance is very poor.
So far, there is no report on the doxorubicin-resistant U87 cell model

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] 1. Experimental materials

[0025] U87 cells were purchased from Chinese Academy of Sciences.

[0026] Doxorubicin (DOX) was purchased from KGI Biotech (Nanjing, China).

[0027] Doxorubicin working solution was prepared with cell culture medium (SH30243.01B+10% FBS, purchased from HyClone, USA).

[0028] 2. Experimental method

[0029] 1) U87 cells were cultured with SH30243.01B+10% FBS+100 U / ml penicillin+0.1 mg / ml streptomycin.

[0030] 2) Start the intervention with DOX at an initial concentration of 1ng / ml, and change to the drug-free medium (SH30243.01B+10%FBS+100U / ml penicillin+0.1mg / ml streptomycin) after 24 hours of DOX administration.

[0031] 3) After the cells grow stably, the shape is plump, there are no floating dead cells, and the passage density is 30%, the cells can grow to 90% in 3 to 5 days, then start normal passage (P) and increase the concentration of DOX.

[0032] Mother cell U87 was intervened with 1ng / ml DOX from the fifth passage (P5) to P1...

Embodiment 2

[0044]In the process of establishing the human astroglioma cell line U87R-DOX, the inventor obtained another doxorubicin-resistant U87 cell model U87R-DOX' in parallel experiments, its IC50 was 685ng / ml, and the drug resistance coefficient (48 hours) was 20.15, the drug resistance coefficient (1 month) was 14.32, and the drug resistance coefficient (6 months) was 12.80. Drug resistance and resistance stability were significantly worse than human astroglioma cell line U87R-DOX.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an adriamycin-resistant U87 cell model and an application thereof. U87 cells are intervened by use of the adriamycin, and then an adriamycin-free culture medium is adopted in stead; after the cells grow to 90% in 3-5 days under the circumstance of stable growth and full form of cells, no floating dead cells and 30% of passage density, normal passage is started and the concentration of the adriamycin is increased; the intervention time of the adriamycin each time is 24 hours; finally, the intervened U87 cells are detected, and consequently, the adriamycin-resistant U87 cell model is obtained; the collection number of the adriamycin-resistant U87 cell model is CCTCC NO: C201531. The cell model is strong in drug resistance, high in drug resistance coefficient, excellent in drug resistance stability, and can be applied to studying the drug resistance mechanism of the brain glioma, searching for the target spot of reversal of drug resistance of the brain glioma and screening drugs for treating the brain glioma or removing the drug resistance of the brain glioma, or to studying the mechanism of tumors causing intractable epilepsy, searching for the target spot of reversal of drug resistance of the epilepsy and screening drugs for treating the epilepsy or removing the drug resistance of the epilepsy.

Description

technical field [0001] The invention relates to the establishment of a cell model, in particular to a doxorubicin-resistant U87 cell model and its application. Background technique [0002] Glioma is the most common primary brain tumor arising from the canceration of glial cells in the brain and spinal cord. The annual incidence is about 3-8 per 100,000 population. Like other tumors (diseases), glioma is also caused by the interaction of innate genetic risk factors and environmental carcinogenic factors. Some known genetic diseases, such as neurofibromatosis (type I) and tuberculous sclerosis, are genetic susceptibility factors for glioma. [0003] The chemotherapeutic drug doxorubicin (DOX) promotes the apoptosis of tumor cells through the intracellular pathway. It is often used in the treatment of glioma, but it is prone to drug resistance, and the effect of chemotherapy after drug resistance is very poor. Ordinary glioma cell lines have limitations in studying the mech...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/09C12Q1/02
Inventor 邵一叶陈英辉
Owner JINSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap